Skip to main content

News

December 12, 2025 in Homepage News, News Highlight

Ractigen Therapeutics Doses First Patient in IIT Study of RAG-18, a Potential Game-Changing saRNA Therapeutic for Duchenne Muscular Dystrophy

NANTONG, China, December 12, 2025 – Ractigen Therapeutics, a pioneering developer of small activating RNA (saRNA)…
Read More
November 17, 2025 in Homepage News, News Highlight

Ractigen Publishes Foundational Paper Detailing Its SCAD Platform for Duplex RNA Delivery to the CNS and Beyond in Molecular Therapy – Nucleic Acids

SUZHOU, China, November 17, 2025 – Ractigen Therapeutics, a clinical-stage biotechnology company, today announced the publication…
Read More
April 9, 2025 in Homepage News, News Highlight, RAG-17

Ractigen’s RAG-17 ALS Data Shines at AAN 2025: Earns Top Award, Phase I Advances

Final results from an Investigator-Initiated Trial presented for the first time, demonstrating favorable safety, significant…
Read More
April 9, 2025 in Company News, Homepage News, Presentations

RAG-17, a Novel siRNA Therapy for SOD1-ALS: Safety and Preliminary Efficacy from a First-in-human Trial (Abstract)

Event: American Academy of Neurology (AAN) 2025 Annual Meeting (San Diego) View Abstract View News:…
Read More
Close Menu